Abstract
Lysophosphatidic acid (LPA; monoacyl-glycerol-3-phosphate) is a lipid mediator that functions as a mitogen and motility factor for many cell types. LPA signals through six specific G protein-coupled receptors, named LPA1–6, which trigger both overlapping and distinct signaling pathways. LPA is produced from extracellular lysophosphatidylcholine by a secreted lysophospholipase D, named autotaxin (ATX), originally identified as an “autocrine motility factor” for tumor cells. ATX–LPA signaling is vital for embryonic development and promotes tumor formation, angiogenesis, and experimental metastasis in mice. Elevated expression of ATX and/or aberrant expression of LPA receptors are found in several human malignancies, while loss of LPA6 function has been implicated in bladder cancer. In this review, we summarize our present understanding of ATX and LPA receptor signaling in cancer.
Similar content being viewed by others
References
Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C. W., Mutoh, T., et al. (2010). LPA receptors: subtypes and biological actions. Annual Review of Pharmacology and Toxicology, 50, 157–186.
Moolenaar, W. H., van Meeteren, L. A., & Giepmans, B. N. (2004). The ins and outs of lysophosphatidic acid signaling. Bioessays, 26, 870–881.
Tokumura, A., Majima, E., Kariya, Y., Tominaga, K., Kogure, K., Yasuda, K., et al. (2002). Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. Journal of Biological Chemistry, 277, 39436–39442.
Umezu-Goto, M., Kishi, Y., Taira, A., Hama, K., Dohmae, N., Takio, K., et al. (2002). Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of Cell Biology, 158, 227–233.
Stracke, M. L., Krutzsch, H. C., Unsworth, E. J., Arestad, A., Cioce, V., Schiffmann, E., et al. (1992). Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. Journal of Biological Chemistry, 267, 2524–2529.
Chun, J., Hla, T., Lynch, K. R., Spiegel, S., & Moolenaar, W. H. (2010). International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacological Reviews, 62, 579–587.
Mills, G. B., & Moolenaar, W. H. (2003). The emerging role of LPA in cancer. Nature Reviews Cancer, 3, 582–591.
van Corven, E. J., Hordijk, P. L., Medema, R. H., Bos, J. L., & Moolenaar, W. H. (1993). Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 90, 1257–1261.
Kranenburg, O., & Moolenaar, W. H. (2001). Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene, 20, 1540–1546.
Guillermet-Guibert, J., Bjorklof, K., Salpekar, A., Gonella, C., Ramadani, F., Bilancio, A., et al. (2008). The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proceedings of the National Academy of Sciences of the United States of America, 105, 8292–8297.
Kranenburg, O., Poland, M., van Horck, F. P., Drechsel, D., Hall, A., & Moolenaar, W. H. (1999). Activation of RhoA by lysophosphatidic acid and Galpha12/13 subunits in neuronal cells: induction of neurite retraction. Molecular Biology of the Cell, 10, 1851–1857.
Stam, J. C., Michiels, F., van der Kammen, R. A., Moolenaar, W. H., & Collard, J. G. (1998). Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO Journal, 17, 4066–4074.
van Leeuwen, F. N., Olivo, C., Grivell, S., Giepmans, B. N., Collard, J. G., & Moolenaar, W. H. (2003). Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. Journal of Biological Chemistry, 278, 400–406.
van Corven, E. J., Groenink, A., Jalink, K., Eichholtz, T., & Moolenaar, W. H. (1989). Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell, 59, 45–54.
Jalink, K., van Corven, E. J., & Moolenaar, W. H. (1990). Lysophosphatidic acid, but not phosphatidic acid, is a potent Ca2(+)-mobilizing stimulus for fibroblasts. Evidence for an extracellular site of action. Journal of Biological Chemistry, 265, 12232–12239.
Stortelers, C., Kerkhoven, R., & Moolenaar, W. H. (2008). Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. BMC Genomics, 9, 387.
Harper, K., Arsenault, D., Boulay-Jean, S., Lauzier, A., Lucien, F., & Dubois, C. M. (2010). Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation. Cancer Research, 70, 4634–4643.
Lee, Z., Cheng, C. T., Zhang, H., Subler, M. A., Wu, J., Mukherjee, A., et al. (2008). Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Molecular Biology of the Cell, 19, 5435–5445.
Stefan, C., Jansen, S., & Bollen, M. (2005). NPP-type ectophosphodiesterases: unity in diversity. Trends in Biochemical Sciences, 30, 542–550.
van Meeteren, L. A., & Moolenaar, W. H. (2007). Regulation and biological activities of the autotaxin-LPA axis. Progress in Lipid Research, 46, 145–160.
Kanda, H., Newton, R., Klein, R., Morita, Y., Gunn, M. D., & Rosen, S. D. (2008). Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nature Immunology, 9, 415–423.
Dusaulcy, R., Rancoule, C., Gres, S., Wanecq, E., Colom, A., Guigne, C., et al. (2011). Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. Journal of Lipid Research, 52(6), 1247–1255.
van Meeteren, L. A., Ruurs, P., Christodoulou, E., Goding, J. W., Takakusa, H., Kikuchi, K., et al. (2005). Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. Journal of Biological Chemistry, 280, 21155–21161.
Nishimasu, H., Okudaira, S., Hama, K., Mihara, E., Dohmae, N., Inoue, A., et al. (2011). Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nature Structural and Molecular Biology, 18, 205–212.
Hausmann, J., Kamtekar, S., Christodoulou, E., Day, J. E., Wu, T., Fulkerson, Z., et al. (2011). Structural basis of substrate discrimination and integrin binding by autotaxin. Nature Structural and Molecular Biology, 18, 198–204.
Pamuklar, Z., Federico, L., Liu, S., Umezu-Goto, M., Dong, A., Panchatcharam, M., et al. (2009). Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. Journal of Biological Chemistry, 284, 7385–7394.
van Meeteren, L. A., Ruurs, P., Stortelers, C., Bouwman, P., van Rooijen, M. A., Pradere, J. P., et al. (2006). Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Molecular and Cellular Biology, 26, 5015–5022.
Tanaka, M., Okudaira, S., Kishi, Y., Ohkawa, R., Iseki, S., Ota, M., et al. (2006). Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. Journal of Biological Chemistry, 281, 25822–25830.
Fotopoulou, S., Oikonomou, N., Grigorieva, E., Nikitopoulou, I., Paparountas, T., Thanassopoulou, A., et al. (2010). ATX expression and LPA signalling are vital for the development of the nervous system. Dev Biol, 339, 451–464.
Koike, S., Keino-Masu, K., & Masu, M. (2010). Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway. Biochemical and Biophysical Research Communications, 400, 66–71.
Matas-Rico, E., Garcia-Diaz, B., Llebrez-Zayas, P., Lopez-Barroso, D., Santin, L., Pedraza, C., et al. (2008). Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus. Molecular and Cellular Neuroscience, 39, 342–355.
Gennero, I., Laurencin-Dalicieux, S., Conte-Auriol, F., Briand-Mesange, F., Laurencin, D., Rue, J., et al. (2011). Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass. Bone, 49(3), 395–403.
Ye, X., Hama, K., Contos, J. J., Anliker, B., Inoue, A., Skinner, M. K., et al. (2005). LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature, 435, 104–108.
Sumida, H., Noguchi, K., Kihara, Y., Abe, M., Yanagida, K., Hamano, F., et al. (2010). LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood, 116, 5060–5070.
Contos, J. J., Ishii, I., Fukushima, N., Kingsbury, M. A., Ye, X., Kawamura, S., et al. (2002). Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Molecular and Cellular Biology, 22, 6921–6929.
Kawagoe, H., Stracke, M. L., Nakamura, H., & Sano, K. (1997). Expression and transcriptional regulation of the PD-Ialpha/autotaxin gene in neuroblastoma. Cancer Research, 57, 2516–2521.
Zhang, G., Zhao, Z., Xu, S., Ni, L., & Wang, X. (1999). Expression of autotaxin mRNA in human hepatocellular carcinoma. Chinese Medical Journal, 112, 330–332.
Yang, S. Y., Lee, J., Park, C. G., Kim, S., Hong, S., Chung, H. C., et al. (2002). Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clinical & Experimental Metastasis, 19, 603–608.
Stassar, M. J., Devitt, G., Brosius, M., Rinnab, L., Prang, J., Schradin, T., et al. (2001). Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. British Journal of Cancer, 85, 1372–1382.
Hoelzinger, D. B., Mariani, L., Weis, J., Woyke, T., Berens, T. J., McDonough, W. S., et al. (2005). Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia, 7, 7–16.
Yang, Y., Mou, L., Liu, N., & Tsao, M. S. (1999). Autotaxin expression in non-small-cell lung cancer. American Journal of Respiratory Cell and Molecular Biology, 21, 216–222.
Baumforth, K. R., Flavell, J. R., Reynolds, G. M., Davies, G., Pettit, T. R., Wei, W., et al. (2005). Induction of autotaxin by the Epstein–Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood, 106, 2138–2146.
Masuda, A., Nakamura, K., Izutsu, K., Igarashi, K., Ohkawa, R., Jona, M., et al. (2008). Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. British Journal of Haematology, 143, 60–70.
Kehlen, A., Englert, N., Seifert, A., Klonisch, T., Dralle, H., Langner, J., et al. (2004). Expression, regulation and function of autotaxin in thyroid carcinomas. International Journal of Cancer, 109, 833–838.
Nam, S. W., Clair, T., Kim, Y. S., McMarlin, A., Schiffmann, E., Liotta, L. A., et al. (2001). Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Research, 61, 6938–6944.
Black, E. J., Clair, T., Delrow, J., Neiman, P., & Gillespie, D. A. (2004). Microarray analysis identifies autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. Oncogene, 23, 2357–2366.
Zirn, B., Samans, B., Wittmann, S., Pietsch, T., Leuschner, I., Graf, N., et al. (2006). Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes, Chromosomes & Cancer, 45, 565–574.
Tice, D. A., Szeto, W., Soloviev, I., Rubinfeld, B., Fong, S. E., Dugger, D. L., et al. (2002). Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. Journal of Biological Chemistry, 277, 14329–14335.
Dufner-Beattie, J., Lemons, R. S., & Thorburn, A. (2001). Retinoic acid-induced expression of autotaxin in N-myc-amplified neuroblastoma cells. Molecular Carcinogenesis, 30, 181–189.
Zirn, B., Samans, B., Spangenberg, C., Graf, N., Eilers, M., & Gessler, M. (2005). All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene, 24, 5246–5251.
Chen, M., & O’Connor, K. L. (2005). Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene, 24, 5125–5130.
Nam, S. W., Clair, T., Campo, C. K., Lee, H. Y., Liotta, L. A., & Stracke, M. L. (2000). Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene, 19, 241–247.
Boucharaba, A., Serre, C. M., Gres, S., Saulnier-Blache, J. S., Bordet, J. C., Guglielmi, J., et al. (2004). Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. The Journal of Clinical Investigation, 114, 1714–1725.
Boucharaba, A., Serre, C. M., Guglielmi, J., Bordet, J. C., Clezardin, P., & Peyruchaud, O. (2006). The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proceedings of the National Academy of Sciences of the United States of America, 103, 9643–9648.
David, M., Wannecq, E., Descotes, F., Jansen, S., Deux, B., Ribeiro, J., et al. (2010). Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One, 5, e9741.
Yu, S., Murph, M. M., Lu, Y., Liu, S., Hall, H. S., Liu, J., et al. (2008). Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. Journal of the National Cancer Institute, 100, 1630–1642.
Taghavi, P., Verhoeven, E., Jacobs, J. J., Lambooij, J. P., Stortelers, C., Tanger, E., et al. (2008). In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene, 27, 6806–6816.
Liu, S., Umezu-Goto, M., Murph, M., Lu, Y., Liu, W., Zhang, F., et al. (2009). Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell, 15, 539–550.
Lin, S., Wang, D., Iyer, S., Ghaleb, A. M., Shim, H., Yang, V. W., et al. (2009). The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology, 136, 1711–1720.
Lin, S., Lee, S. J., Shim, H., Chun, J., & Yun, C. C. (2010). The absence of LPA receptor 2 reduces the tumorigenesis by Apc Min mutation in the intestine. American Journal of Physiology. Gastrointestinal and Liver Physiology, 299, G1128–G1138.
Nakai, Y., Ikeda, H., Nakamura, K., Kume, Y., Fujishiro, M., Sasahira, N., et al. (2011). Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clinical Biochemistry, 44(8–9), 576–581.
Lu, Y., Lemon, W., Liu, P. Y., Yi, Y., Morrison, C., Yang, P., et al. (2006). A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Medicine, 3, e467.
Lee, S., Jeong, J., Majewski, T., Scherer, S. E., Kim, M. S., Tuziak, T., et al. (2007). Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proceedings of the National Academy of Sciences of the United States of America, 104, 13732–13737.
Pasternack, S. M., von Kugelgen, I., Aboud, K. A., Lee, Y. A., Ruschendorf, F., Voss, K., et al. (2008). G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nature Genetics, 40, 329–334.
Yanagida, K., Masago, K., Nakanishi, H., Kihara, Y., Hamano, F., Tajima, Y., et al. (2009). Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. Journal of Biological Chemistry, 284(26), 17731–17741.
Kaplan, M. H., Smith, D. I., & Sundick, R. S. (1993). Identification of a G protein coupled receptor induced in activated T cells. Journal of Immunology, 151, 628–636.
Majewski, T., Lee, S., Jeong, J., Yoon, D. S., Kram, A., Kim, M. S., et al. (2008). Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Laboratory Investigation, 88, 694–721.
Song, H., Ramus, S. J., Shadforth, D., Quaye, L., Kjaer, S. K., Dicioccio, R. A., et al. (2006). Common variants in RB1 gene and risk of invasive ovarian cancer. Cancer Research, 66, 10220–10226.
Kazantseva, A., Goltsov, A., Zinchenko, R., Grigorenko, A. P., Abrukova, A. V., Moliaka, Y. K., et al. (2006). Human hair growth deficiency is linked to a genetic defect in the phospholipase gene LIPH. Science, 314, 982–985.
Crawford, J. M. (2008). The origins of bladder cancer. Laboratory Investigation, 88, 686–693.
Baker, D. L., Fujiwara, Y., Pigg, K. R., Tsukahara, R., Kobayashi, S., Murofushi, H., et al. (2006). Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. Journal of Biological Chemistry, 281, 22786–22793.
Durgam, G. G., Virag, T., Walker, M. D., Tsukahara, R., Yasuda, S., Liliom, K., et al. (2005). Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. Journal of Medicinal Chemistry, 48, 4919–4930.
Zhang, H., Xu, X., Gajewiak, J., Tsukahara, R., Fujiwara, Y., Liu, J., et al. (2009). Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Research, 69, 5441–5449.
van Meeteren, L. A., Brinkmann, V., Saulnier-Blache, J. S., Lynch, K. R., & Moolenaar, W. H. (2008). Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Letters, 266, 203–208.
Gupte, R., Patil, R., Liu, J., Wang, Y., Lee, S. C., Fujiwara, Y., et al. (2011). Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. ChemMedChem, 6, 922–935.
Albers, H. M., Dong, A., van Meeteren, L. A., Egan, D. A., Sunkara, M., van Tilburg, E. W., et al. (2010). Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proceedings of the National Academy of Sciences of the United States of America, 107, 7257–7262.
Albers, H. M., van Meeteren, L. A., Egan, D. A., van Tilburg, E. W., Moolenaar, W. H., & Ovaa, H. (2010). Discovery and optimization of boronic acid based inhibitors of autotaxin. Journal of Medicinal Chemistry, 53, 4958–4967.
Gierse, J., Thorarensen, A., Beltey, K., Bradshaw-Pierce, E., Cortes-Burgos, L., Hall, T., et al. (2010). A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. Journal of Pharmacology and Experimental Therapeutics, 334, 310–317.
Acknowledgments
Work related to this review is supported by grants from the Dutch Cancer Society and the Netherlands Organization of Pure Research. We thank Anastassis Perrakis for designing Fig. 1.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Houben, A.J.S., Moolenaar, W.H. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev 30, 557–565 (2011). https://doi.org/10.1007/s10555-011-9319-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-011-9319-7